Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.37 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17513413 | 1.00 | SLC6A1 (0.37) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL3698542 | 1.00 | SLC6A1 (0.37) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL28493616 | 0.95 | EPHX1 (0.39) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL1441784 | 0.90 | CHRM3 (0.35) | SMN1; SMN2DPP4L3MBTL1SSTR4CCNE1 | |
| SCHEMBL954528 | 0.90 | CHRM3 (0.35) | SMN1; SMN2DPP4L3MBTL1SSTR4CCNE1 | |
| SCHEMBL954529 | 0.90 | CHRM3 (0.35) | SMN1; SMN2DPP4L3MBTL1SSTR4CCNE1 | |
| Methane SCHEMBL27926432 | 0.89 | CHRM3 (0.34) | DPP4L3MBTL1SSTR4CCNE1CDK2 | |
| Hydrochloric Acid SCHEMBL28057619 | 0.89 | DPP4 (0.35) | DPP4L3MBTL1SSTR4CCNE1CDK2 | |
| SCHEMBL16505644 | 0.87 | EPHX1 (0.40) | SMN1; SMN2EPHX1DPP4L3MBTL1CCNE1 | |
| Bicarbonate SCHEMBL1532914 | 0.87 | CHRM3 (0.36) | SLC6A1SLC6A11LMNASLC6A13DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111094265-B | Pyrazole derivative compound and use thereof | 韩美药品株式会社 | 2023-07-25 | — | — | CN | disclosed |
| EP-3381896-B1 | BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-01-18 | — | — | EP | disclosed |
| EP-3790870-A1 | CYCLOPENTANE COMPOUNDS | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) | 2021-03-17 | — | — | EP | disclosed |
| US-10723742-B2 | Biphenyl compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| WO-2019215268-A1 | CYCLOPENTANE COMPOUNDS | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
| US-20180354960-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-3381896-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-10-03 | — | — | EP | disclosed |
| CN-104072489-A | Therapeutic isoxazole compounds | HELICON THERAPEUTICS INC | 2014-10-01 | — | — | CN | disclosed |
| CN-101820764-B | Therapeutic isoxazole compounds | HELICON THERAPEUTICS INC | 2014-06-04 | — | — | CN | disclosed |
| US-8138207-B2 | Antidiabetic agents, carbohydrate and lipid metabolic disorders; 2-(amino-substituted piperidin-1-yl)benzimidazoles; N-[2-(3-Aminopiperidin-1-yl)-1-(3-methylbut-2-enyl)-1H-benzimidazol-6-y]-benzamide trifluoroacetic acid salt for example; use in combination with other drugs | SANOFI-AVENTIS (FR) | 2012-03-20 | — | — | US | disclosed |
| US-8003668-B2 | Use of 2-(amino-substituted piperidin-1-yl)benzimidazoles as antidiabetic agents, or to treat carbohydrate and lipid metabolic disorders; use in combination with other drugs; N-[2-(3-Aminopiperidin-1-yl)-1-(3-methylbut-2-enyl)-1H-benzimidazol-6-yl]-benzenesulfonamide or salts for example | SANOFI-AVENTIS (FR) | 2011-08-23 | — | — | US | disclosed |
| CN-101820764-A | Therapeutic isoxazole compounds | HELICON THERAPEUTICS INC | 2010-09-01 | — | — | CN | disclosed |
| US-20080090870-A1 | AMINO-SUBSTITUTED 8-N-BENZIMIDAZOLES AND METHODS FOR THEIR USE IN BLOOD SUGAR DISORDERS | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
| US-20080090869-A1 | AMINOCARBONYL-SUBSTITUTED 8-N-BENZIMIDAZOLES, METHODS FOR THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | SANOFI-AVENTIS (FR) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090869-A1 | AMINOCARBONYL-SUBSTITUTED 8-N-BENZIMIDAZOLES, METHODS FOR THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | GPR119, SLC5A1, SLC2A8 | SLC6A1 1744/4885SLC6A11 1650/4885TSHR 2714/4885 |
| US-10723742-B2 | Biphenyl compound or salt thereof | KDM1B, BMI1, HDAC1 | SLC6A1 1027/4885SLC6A11 749/4885TSHR 4543/4885 |
| US-20180354960-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | KDM1B, HDAC1, DOT1L | SLC6A1 1195/4885SLC6A11 866/4885TSHR 4534/4885 |
| US-20080090870-A1 | AMINO-SUBSTITUTED 8-N-BENZIMIDAZOLES AND METHODS FOR THEIR USE IN BLOOD SUGAR DISORDERS | GPR119, SLC5A1, SLC2A8 | SLC6A1 660/4885SLC6A11 684/4885TSHR 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.